Case Report: Fia Plus Venetoclax in a Patient on Hemodialysis

Authors

Jacob E Herstein
Kayleigh R Marx
J Michael Savoy
Wei Ying Jen
Musa Yilmaz
Nicholas J Short
Ghayas C Issa
Farhad Ravandi
Tapan M Kadia
Naval G Daver
Courtney D DiNardo

Language

English

Publication Date

1-1-2025

Journal

Frontiers in Oncology

DOI

10.3389/fonc.2025.1740357

PMID

41626172

PMCID

PMC12852021

PubMedCentral® Posted Date

1-15-2026

PubMedCentral® Full Text Version

Post-print

Abstract

The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).

Keywords

acute myeloid leukemia, case report, chemotherapy, hematologic oncology, hemodialysis

Published Open-Access

yes

Recommended Citation

Herstein, Jacob E; Marx, Kayleigh R; Savoy, J Michael; et al., "Case Report: Fia Plus Venetoclax in a Patient on Hemodialysis" (2025). Faculty, Staff and Student Publications. 5581.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5581